Skip to main content

Table 2 Percent of responders in um-PEA TP and TP groups at different follow-up times

From: The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms

Parameters Goals Percent of responders in um-PEA TP group/TP group at different follow-up times
T1 T2 T3
VAS Reduction       
≥2 3.3 0 90*** 16 100*** 68
≥3 3.3 0 30** 0 63.3*** 8
≥4 0 0 0 0 20* 0
VAS scorea ≤ 3 0 0 0 0 0 0
DN4 Reduction       
≥1 46. 7** 16 93.3*** 36 100.0 96
≥2 6. 7 0 73.3*** 4 86. 7*** 20
DN4 scoreb < 4 3. 3 0 6. 7 0 76. 7*** 0
ODQ Reduction       
≥10 86.7** 48
≥15 70.0** 24
≥20 53.3** 16
  1. aPercentage of patients who achieved a VAS score ≤ 3
  2. bPercentage of patients who achieved a DN4 score < 4
  3. *p < 0.05
  4. **p < 0.01
  5. ***p < 0.0001